Optimization, scale-up, and validation ISSUES in FILTRATION of Biopharmaceuticals, Part II - - BioPharm International

ADVERTISEMENT

Optimization, scale-up, and validation ISSUES in FILTRATION of Biopharmaceuticals, Part II

Process Development The output of process development is a proposal for a system containing a particular membrane and membrane area, controlled to specific setpoints for crossflow, pressure, and temperature (within some reasonable ranges), for processing of a particular volume of a product stream with fixed buffers, cleaned per a set protocol and re-used up to a specified number of times. During the development phase, this particular combination of physical components and operating strategy has been shown to result in a process that meets the success criteria for yield, cycle time, robustness, and economics and final product that meets the success criteria for quality and purity. It is this completely defined process, once it has been accurately scaled up and the suitability of the system design has been verified, that must be validated through an overall validation scheme that includes process characterization, process validation, and cleaning validation.

Process Scale-Up and Verification of System Design Suitability Although not explicitly part of validation, proper scale-up and design of the manufacturing system is critical to ensuring that the process results achieved at small scale can be reproduced at industrial scale without encountering problems. Again, the success criteria must be considered. Not only must the manufacturing system be able to provide the flow rate, pressure, temperature, and volume handling capability as specified by the development work, but it also must not have any adverse effects on the product yield, quality, purity, or consistency. Specific areas of system design that should be carefully considered for the potential for adverse effects are: minimization of working volume, thorough drainability, proper flow distribution, the choice of recirculation pump, any points of air-liquid interface, adequate mixing, minimization of deadlegs, and compatibility of materials and extractables from all fluid contacting materials with any product, buffer, or cleaning stream.

One area where system design explicitly falls under the validation umbrella is in the validation of extractables from any wetted components in the product stream. All fluid contacting materials from every component in the large-scale system must be compatible with all product, buffer, and cleaning solution streams and must not add contaminants to the product. This is of particular importance if the TFF unit operation is near the end of the purification process. Equipment vendors for the biopharmaceutical industry generally ensure that their materials of construction meet USP requirements for Class VI Biological Tests for Plastics and are non-toxic per USP General Mouse Safety Test.4 In addition, effluent from any filters must test negative for USP oxidizable substances after an appropriate flush volume. In cases where vendors do not have appropriate test results available, extractables validation is most easily carried out on individual components as opposed to the full-scale system. However, depending on the design of carryover studies, which will be discussed later, it is possible to include any component extractables testing with carryover results.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here